Organization · Venture Capital
Longevity Vision
Longevity Vision is a venture capital fund based in New York that invests in technologies aimed at disrupting life sciences and healthcare, focusing on longevity and age-related diseases.
Overview
What Longevity Vision does
What Longevity Vision is
Longevity Vision is a venture capital fund based in New York that invests in technologies aimed at disrupting life sciences and healthcare, focusing on longevity and age-related diseases.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder
- Last reviewed
- March 31, 2026
Official channels
Find Longevity Vision elsewhere
Open the official website or a supported primary organization account.
Capability profile
Longevity Vision as a funder
Investment thesis
Longevity Vision focuses on supporting breakthroughs in longevity and healthcare, targeting innovative solutions for age-related diseases through validated scientific concepts and viable business models.
Focus narrative
Longevity Vision invests in a diverse range of sectors related to longevity and healthcare, including gene therapy, AI-based drug discovery, cancer detection, and organ regeneration technologies. The organization targets multiple stages of development, aiming to cover a broad spectrum of diseases through its portfolio, with a focus on advancing therapies that can significantly impact aging.
Value beyond capital
Longevity Vision adds value to its portfolio companies by leveraging its extensive network of experts in longevity and healthcare, providing strategic guidance, and facilitating access to resources necessary for growth and development. The organization emphasizes a differentiated and de-risked investment strategy, focusing on validated scientific concepts with clear pathways to market.
Focus and fit
- Stages
- Growth Equity
- Regions
- Global · United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 18
Portfolio context
Notable portfolio companies include Tessera Therapeutics, which specializes in gene writing technology for genetic diseases; LyGenesis, focusing on organ regeneration using lymph nodes; and Insilico Medicine, an AI drug discovery platform that rapidly develops drug candidates. Other companies include Biolinq, a wearable biosensor patch, and various platforms targeting cancer detection and chronic disease treatment.
Common questions
What to know about Longevity Vision
Upseed classifies Longevity Vision under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 31, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.